Garzotto M - Search Results

1

Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15.

Huang CY, Beer TM, Higano CS, True LD, Vessella R, Lange PH, Garzotto M, Nelson PS. Huang CY, et al. Among authors: garzotto m. Clin Cancer Res. 2007 Oct 1;13(19):5825-33. doi: 10.1158/1078-0432.CCR-07-1037. Clin Cancer Res. 2007. PMID: 17908975 Clinical Trial.

2

Syndrome of inappropriate antidiuretic hormone secretion: a rare complication of prostate cancer.

Garzotto M, Beer TM. Garzotto M, et al. J Urol. 2001 Oct;166(4):1386. J Urol. 2001. PMID: 11547083 No abstract available.

3

Weekly high-dose calcitriol and docetaxel in advanced prostate cancer.

Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD. Beer TM, et al. Among authors: garzotto m. Semin Oncol. 2001 Aug;28(4 Suppl 15):49-55. doi: 10.1016/s0093-7754(01)90155-1. Semin Oncol. 2001. PMID: 11685729 Clinical Trial.

4

Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.

Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Beer TM, et al. Among authors: garzotto m. J Clin Oncol. 2003 Jan 1;21(1):123-8. doi: 10.1200/jco.2003.05.117. J Clin Oncol. 2003. PMID: 12506180 Clinical Trial.

5

Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy.

Beer TM, Garzotto M, Eilers KM, Lemmon D. Beer TM, et al. Among authors: garzotto m. J Urol. 2003 May;169(5):1738-41. doi: 10.1097/01.ju.0000059584.47272.9d. J Urol. 2003. PMID: 12686821 Clinical Trial.

6

A comparison of CT scan to transrectal ultrasound-measured prostate volume in untreated prostate cancer.

Hoffelt SC, Marshall LM, Garzotto M, Hung A, Holland J, Beer TM. Hoffelt SC, et al. Among authors: garzotto m. Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):29-32. doi: 10.1016/s0360-3016(03)00509-1. Int J Radiat Oncol Biol Phys. 2003. PMID: 12909212 Clinical Trial.

7

Intermittent chemotherapy in metastatic androgen-independent prostate cancer.

Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Beer TM, et al. Among authors: garzotto m. Br J Cancer. 2003 Sep 15;89(6):968-70. doi: 10.1038/sj.bjc.6601232. Br J Cancer. 2003. PMID: 12966410 Free PMC article. Clinical Trial.

8

Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.

Garzotto M, Hudson RG, Peters L, Hsieh YC, Barrera E, Mori M, Beer TM, Klein T. Garzotto M, et al. Cancer. 2003 Oct 1;98(7):1417-22. doi: 10.1002/cncr.11668. Cancer. 2003. PMID: 14508828 Free article.

9

Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma.

Beer TM, Eilers KM, Garzotto M, Hsieh YC, Mori M. Beer TM, et al. Among authors: garzotto m. Cancer. 2004 Feb 15;100(4):758-63. doi: 10.1002/cncr.20024. Cancer. 2004. PMID: 14770432 Free article. Clinical Trial.

10

Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.

Beer TM, Garzotto M, Eilers KM, Lemmon D, Wersinger EM. Beer TM, et al. Among authors: garzotto m. Urology. 2004 Feb;63(2):342-7. doi: 10.1016/j.urology.2003.09.045. Urology. 2004. PMID: 14972486

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters